Cadila Pharma launches generic Sitagliptin versions to treat uncontrolled type-II diabetes

Cadila Pharma has launched the generic versions of Sitagliptin in India under the brand names Jankey and Sitenali to address type-II diabetes, a company statement said.

Sitagliptin is a drug from the class of DPP-4 inhibitors, and a one-of-its-kind drug for the treatment of high glucose levels in the blood, also known as hyperglycaemia. High blood glucose can lead to life-threatening complications such as atherosclerosis, stroke, heart attack, retinopathy, neuropathy and nephropathy, the statement added.

It also mentioned that Sitagliptin has a strong clinical profile and the potential to revolutionise the treatment of type-II diabetes for millions of people who do not achieve the targetted blood sugar level with currently available anti-diabetic medications. It delivers unprecedented HbA1c control, weight neutral with a well-established CV safety profile and nominal risk of hypoglycaemia compared to other DPP-4 inhibitors class of drug.

According to a recently published report, approximately 7.7 crore people in India are suffering from diabetes. Metformin is currently the drug of choice for controlling blood glucose levels, but in the majority of the patients, it either does not provide optimum control, or is not tolerated, claimed the statement.